Reference data : LOINC code

Filter


Clear filter

Results
108,248 results found
Loinc Number Component Property System Time aspect ScaleType MethodType Relat_nms loincStatus Long Common name answerList chngType <span class='defaultText'>DefinitionDescription</span> dtLastCh exactCmspy exampleUnits exmplAnswers externalCopyrightNotice formula hl7FieldSubfieldId InpcPercentage ipccUnits loincClass loincFinal loincNum mapTo methodTyp molarMass naaccrId orderObs panelElements reference scope setRoot shortName source surveyQuestSrc surveyQuestText unitsRequired acssym relatedNames2 VersionLastChanged VersionFirstRelease ValidHL7AttachmentRequest PanelType AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
101325-9 Tub &or shower transfer - functional goal Find ^Patient RptPeriod Ord CMS Assessment &nbsp; ACTIVE MDS v3.0 - RAI v1.18.11 - Tub/shower transfer - functional goal [CMS Assessment] &nbsp; MAJ DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.CMS &nbsp; 101325-9 &nbsp; CMS Assessment &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Centers for Medicare and Medicaid Assessment; Finding; Findings; Ordinal; Ql; Qual; Qualitative; Report period; Screen; Survey 2.77 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; 0
101326-7 MDS v3.0 - RAI v1.18.11 - Pain assessment interview - ^Patient RptPeriod - CMS Assessment &nbsp; ACTIVE MDS v3.0 - RAI v1.18.11 - Pain assessment interview during assessment period [CMS Assessment] &nbsp; PANEL DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PANEL.SURVEY.CMS &nbsp; 101326-7 &nbsp; CMS Assessment &nbsp; &nbsp; Subset &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey 2.75 2.74 &nbsp; Organizer &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101327-5 Nutritional approaches - on admission Find ^Patient RptPeriod Nom CMS Assessment &nbsp; ACTIVE MDS v3.0 - RAI v1.18.11 - Nutritional approaches - on admission during assessment period [CMS Assessment] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.CMS &nbsp; 101327-5 &nbsp; CMS Assessment &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Centers for Medicare and Medicaid Assessment; Finding; Findings; Nominal; Report period; Survey 2.74 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101328-3 Nutritional approaches - at discharge Find ^Patient RptPeriod Nom CMS Assessment &nbsp; ACTIVE MDS v3.0 - RAI v1.18.11 - Nutritional approaches - at discharge during assessment period [CMS Assessment] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.CMS &nbsp; 101328-3 &nbsp; CMS Assessment &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Centers for Medicare and Medicaid Assessment; Disch; Finding; Findings; Nominal; Report period; Survey 2.74 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101329-1 Participation in assessment and goal setting - ^Patient RptPeriod - CMS Assessment &nbsp; ACTIVE MDS v3.0 - RAI v1.18.11 - Participation in assessment and goal setting [CMS Assessment] &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PANEL.SURVEY.CMS &nbsp; 101329-1 &nbsp; CMS Assessment &nbsp; &nbsp; Subset &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey 2.81 2.74 &nbsp; Organizer &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Release 2.78: PanelType: corrected error - should be Subset Organizer; Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; 0
10133-7 T' wave amplitude.lead I Elpot Heart Pt Qn EKG &nbsp; ACTIVE T' wave amplitude in lead I &nbsp; MIN DefinitionDescription &nbsp; &nbsp; mV &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; EKG.MEAS &nbsp; 10133-7 &nbsp; EKG &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 T' wave Amp L-I &nbsp; &nbsp; &nbsp; Y &nbsp; Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; T prime; T' wave Amp L-I; T wave Amp L-I; Voltage 2.48 1.0i &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mV &nbsp; &nbsp; &nbsp; 0
101330-9 Number of venous and arterial ulcers Num ^Patient RptPeriod Qn CMS Assessment &nbsp; ACTIVE MDS v3.0 - RAI v1.18.11 - Number of venous and arterial ulcers during assessment period [CMS Assessment] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; # &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.CMS &nbsp; 101330-9 &nbsp; CMS Assessment &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Centers for Medicare and Medicaid Assessment; Cnt; Count; No; Num; Number; QNT; Quan; Quant; Quantitative; Report period; Survey 2.74 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; {#} &nbsp; &nbsp; &nbsp; 0
101331-7 Ulcers, wounds and skin problems Find ^Patient RptPeriod Nom CMS Assessment &nbsp; ACTIVE MDS v3.0 - RAI v1.18.11 - Ulcers, wounds and skin problems during assessment period [CMS Assessment] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.CMS &nbsp; 101331-7 &nbsp; CMS Assessment &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Centers for Medicare and Medicaid Assessment; Finding; Findings; Integument; Nominal; Report period; Survey 2.74 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101332-5 Reason referral to local contact agency not made Find ^Patient RptPeriod Nom CMS Assessment &nbsp; ACTIVE MDS v3.0 - RAI v1.18.11 - Reason referral to local contact agency not made [CMS Assessment] &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.CMS &nbsp; 101332-5 &nbsp; CMS Assessment &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Centers for Medicare and Medicaid Assessment; Finding; Findings; Nominal; Report period; Survey 2.81 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; 0
101333-3 Determination of pressure injury risk Find ^Patient RptPeriod Nom CMS Assessment &nbsp; ACTIVE MDS v3.0 - RAI v1.18.11 - Determination of pressure injury risk [CMS Assessment] &nbsp; MAJ DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.CMS &nbsp; 101333-3 &nbsp; CMS Assessment &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Centers for Medicare and Medicaid Assessment; Finding; Findings; Nominal; pressure injury; Pressure ulcer; Pressure Ulcers; Report period; Survey; Ulcer 2.77 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; 0
101334-1 Etizolam/Creatinine MRto Urine Pt Qn Confirm &nbsp; ACTIVE Etizolam/Creatinine [Mass Ratio] in Urine by Confirmatory method &nbsp; NAM DefinitionDescription &nbsp; &nbsp; ng/mg creatinine &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101334-1 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Etizolam/Creat Ur Cfm &nbsp; &nbsp; &nbsp; N &nbsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; Depas; DRUG/TOXICOLOGY; Drugs; etizolam; GCMS; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn; Y-7131 2.76 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ng/mg{creat} &nbsp; &nbsp; Release 2.76: COMPONENT: component to reflect mrto modeling; 0
101335-8 Etizolam PrThr Urine Pt Ord Confirm &nbsp; ACTIVE Etizolam [Presence] in Urine by Confirmatory method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 101335-8 &nbsp; Confirm &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Etizolam Ur Ql Cfm &nbsp; &nbsp; &nbsp; N &nbsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Depas; DRUG/TOXICOLOGY; Drugs; etizolam; GCMS; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn; Y-7131 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101336-6 W little r super little b Ag PrThr RBC Pt Ord &nbsp; &nbsp; ACTIVE Wr sup(b) Ag [Presence] on Red Blood Cells &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; BLDBK &nbsp; 101336-6 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Wr sup(b) Ag RBC Ql &nbsp; &nbsp; &nbsp; N &nbsp; Antigen; Antigens; BLOOD BANK; Erythrocytes; Ordinal; Point in time; PR; QL; Qual; Qualitative; R prime; Random; Red blood cells; Red blood corpusles; Right; Screen; Wr sup(b) 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101337-4 Treatment preferences under certain health conditions Find ^Patient Pt Nar Reported &nbsp; ACTIVE Treatment preferences under certain health conditions [Reported] &nbsp; ADD DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; SURVEY.GNHLTH &nbsp; 101337-4 &nbsp; Reported &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Finding; Findings; Narrative; Point in time; Random; Report; SDOH; Survey; SURVEY.GNHLTH; Tx; Tx pref under certain health conditions 2.74 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101338-2 Coagulation factor X inhibitor ACnc PPP Pt Qn Chromo &nbsp; ACTIVE Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Chromogenic method &nbsp; MIN DefinitionDescription &nbsp; &nbsp; arb U/L &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; COAG &nbsp; 101338-2 &nbsp; Chromo &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Fact X Inhib PPP Chro-aCnc &nbsp; &nbsp; &nbsp; N &nbsp; Arbitrary concentration; Autoprothrombin III; Chromogenic assay; Coag; ENZY; Enzymatic assay; Fac; Fact; Fact X; Fact X Inhib; Factor 10; FX; Inhib; Inhibit; Plas; Platelet poor plasma; Point in time; Prothrombokinase; QNT; Quan; Quant; Quantitative; Random; Stuart-prower factor 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [arb'U]/L &nbsp; &nbsp; &nbsp; 0
101339-0 Cholesterol PrThr Fibroblasts Pt Ord Filipin stain &nbsp; ACTIVE Cholesterol [Presence] in Fibroblast by Filipin stain &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PATH &nbsp; 101339-0 &nbsp; Filipin stain &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Cholest Fib Ql Filipin stain &nbsp; &nbsp; &nbsp; N &nbsp; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Fib; Fibr; Lipid; Ordinal; PATHOLOGY; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
10134-5 T' wave amplitude.lead II Elpot Heart Pt Qn EKG &nbsp; ACTIVE T' wave amplitude in lead II &nbsp; MIN DefinitionDescription &nbsp; &nbsp; mV &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; EKG.MEAS &nbsp; 10134-5 &nbsp; EKG &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 T' wave Amp L-II &nbsp; &nbsp; &nbsp; Y &nbsp; 2; Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; T prime; T' wave Amp L-II; T wave Amp L-II; Voltage 2.48 1.0i &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mV &nbsp; &nbsp; &nbsp; 0
101340-8 Aeromonas sp DNA PrThr Stool Pt Ord Probe.amp.tar &nbsp; ACTIVE Aeromonas sp DNA [Presence] in Stool by NAA with probe detection &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 101340-8 &nbsp; Probe.amp.tar &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Aeromonas DNA Stl Ql NAA+probe &nbsp; &nbsp; &nbsp; N &nbsp; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Bowel movement; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Faecal; Faeces; Fecal; Feces; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; species; spp; Stl; Stool = Fecal; Strand Displacement Amplification; TMA; Transcription mediated amplification 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101341-6 BK virus DNA ACnc Bld Pt Qn Probe.amp.tar &nbsp; ACTIVE BK virus DNA [Units/volume] (viral load) in Blood by NAA with probe detection &nbsp; MIN DefinitionDescription &nbsp; &nbsp; IU/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 101341-6 &nbsp; Probe.amp.tar &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 BKV DNA Bld NAA+probe-aCnc &nbsp; &nbsp; &nbsp; N &nbsp; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; BKV; Blood; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load; WB; Whole blood 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [IU]/mL &nbsp; &nbsp; &nbsp; 0
101342-4 JC virus DNA ACnc Ser/Plas Pt Qn Probe.amp.tar &nbsp; ACTIVE JC virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection &nbsp; MIN DefinitionDescription &nbsp; &nbsp; IU/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 101342-4 &nbsp; Probe.amp.tar &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 JCPyV DNA SerPl NAA+probe-aCnc &nbsp; &nbsp; &nbsp; N &nbsp; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Human polyomavirus 2; JC Polyomavirus; JCPyV; JCV; John Cunningham Virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [IU]/mL &nbsp; &nbsp; &nbsp; 0
101343-2 Erythrocytes.parasite sp infected/Cells NFr Bld Pt Qn &nbsp; &nbsp; ACTIVE Erythrocytes.parasite sp infected/cells in Blood &nbsp; NAM DefinitionDescription &nbsp; &nbsp; % &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 101343-2 &nbsp; &nbsp; &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Parasite infected RBC Bld-NFr &nbsp; &nbsp; &nbsp; N &nbsp; Blood; Cell; Cellularity; Discocytes; Erthrocyte; Erythrocyte; Microbiology; Number Fraction; Parasite infected RBC; Parasites; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; RBC; RBCS; Red blood cell; Red blood cells; Red blood corpuscle; Red blood corpusles; Red cell; Red cells; species; spp; WB; Whole blood 2.79 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; % &nbsp; &nbsp; Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; 0
101344-0 Acute febrile illness global pathogens panel - Bld Pt - Non-probe.amp.tar &nbsp; ACTIVE Acute febrile illness global pathogens panel - Blood by NAA with non-probe detection &nbsp; PANEL DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PANEL.MICRO &nbsp; 101344-0 &nbsp; Non-probe.amp.tar &nbsp; &nbsp; Order &nbsp; &nbsp; &nbsp; 0 Acute feb illness glob path pnl Bld NAA+non-probe &nbsp; &nbsp; &nbsp; N &nbsp; 3 Self-Sustaining Sequence Replication; 3SR SR; Acute feb illness glob path pnl; Amplif; Amplification; Amplified; Blood; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Pan; PANEL.MICROBIOLOGY; Panl; PCR; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood 2.77 2.74 &nbsp; Panel &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101345-7 Candida krusei DNA PrThr XXX Pt Ord Probe.amp.tar &nbsp; ACTIVE Candida krusei DNA [Presence] in Specimen by NAA with probe detection &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; MICRO &nbsp; 101345-7 &nbsp; Probe.amp.tar &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 C krusei DNA Spec Ql NAA+probe &nbsp; &nbsp; &nbsp; N &nbsp; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C krusei; Cand; Candidiasis; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified 2.75 2.74 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
101346-5 MDS v3.0 - RAI v1.18.11 - Special Treatments, Procedures, and Programs - ^Patient RptPeriod - CMS Assessment &nbsp; ACTIVE MDS v3.0 - RAI v1.18.11 - Special Treatments, Procedures, and Programs [CMS Assessment] &nbsp; PANEL DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PANEL.SURVEY.CMS &nbsp; 101346-5 &nbsp; CMS Assessment &nbsp; &nbsp; Subset &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Special Txs, procedures and programs; Survey; Tx; Txs 2.78 2.74 &nbsp; Organizer &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; 0
101347-3 Return to Community - ^Patient RptPeriod - CMS Assessment &nbsp; ACTIVE MDS v3.0 - RAI v1.18.11 - Return to community [CMS Assessment] &nbsp; PANEL DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PANEL.SURVEY.CMS &nbsp; 101347-3 &nbsp; CMS Assessment &nbsp; &nbsp; Subset &nbsp; &nbsp; &nbsp; 0 &nbsp; &nbsp; &nbsp; &nbsp; N &nbsp; Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey 2.78 2.74 &nbsp; Organizer &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; 0
108,248 results found